News

Show
news from

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

Yellowstone Biosciences appoints Dr. Ita O’Kelly, previously Executive Director Product Management at Immunocore, as its Chief Operating Officer and a member of its Leadership Team

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain

Load more

Search